Yasunobu Tanaka

Yasunobu Tanaka joined OIST in April 2023 as a secondment by a startup company, Corundum Systems Biology, Inc. (CSB), and was appointed Chief Operating Officer and Deputy Project Leader of the COI-NEXT Center at OIST.  Before joining OIST, he was an executive director at CSB since September 2020, and he was responsible for research funding programs and academic relations in the microbiome arena.  He started his industry career at Nitto Denko in 1998, where he played the leading role in the development of a novel liposomal siRNA drug pipeline for liver and lung fibrosis indications with responsibilities of global clinical development, IP portfolio management, and due diligence that eventually led to successful license out deal to mega pharma.